Basic Information
| LncRNA/CircRNA Name | TSlnc8 |
| Synonyms | NA |
| Region | GRCh38_8:29673922-29748109 |
| Ensemble | ENSG00000251191 |
| Refseq | NR_026765 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Luciferase reporter assay |
| Sample | Breast cancer cell lines (MDA-MB-231, HCC1559, BT549, UACC-812, and MDA-MB-453), Normal breast epithelial cell (NBEC) lines, The breast cancer tissues and normal adjacent tissues |
| Expression Pattern | up-regulated |
| Function Description | TSLNC8 is significantly increased in breast cancer tissues and cell lines. Up-regulation of TSLNC8 reduces the proliferation capacity of breast cancer cells and the transition from G1 to S phase of the cell cycle. Further analysis indicated that TSLNC8 could directly bind to miR-214-3p. Up-regulation of miR-214-3p may attenuate the suppressive role of TSLNC8 on the proliferation capacity of breast cancer cells. Moreover, miR-214-3p was found to directly interact with the 3`-untranslated region (UTR) of Forkhead box P2 (FOXP2) in luciferase assays, suggesting that FOXP2 may be one of the downstream targets of miR-412-3p. |
| Pubmed ID | 31646574 |
| Year | 2019 |
| Title | LncRNA TSLNC8 inhibits proliferation of breast cancer cell through the miR-214-3p/FOXP2 axis |
External Links
| Links for TSlnc8 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |